BioLife Solutions (NASDAQ:BLFS) Lowered to Sell Rating by StockNews.com

BioLife Solutions (NASDAQ:BLFS) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.

BLFS has been the subject of several other reports. HC Wainwright increased their target price on BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. KeyCorp increased their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Northland Securities upped their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. Finally, Benchmark reissued a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $29.86.

BioLife Solutions Trading Down 12.0 %

BioLife Solutions stock traded down $3.12 during trading hours on Monday, reaching $22.84. 1,137,707 shares of the company’s stock traded hands, compared to its average volume of 356,467. BioLife Solutions has a fifty-two week low of $14.84 and a fifty-two week high of $29.55. The firm’s 50 day moving average is $26.28 and its 200-day moving average is $25.56. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of -21.55 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last issued its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. The firm had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same quarter last year, the business earned ($0.21) earnings per share. On average, analysts predict that BioLife Solutions will post -0.3 earnings per share for the current year.

Insider Activity at BioLife Solutions

In other BioLife Solutions news, CFO Troy Wichterman sold 987 shares of BioLife Solutions stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the transaction, the chief financial officer now directly owns 121,779 shares of the company’s stock, valued at $3,290,468.58. The trade was a 0.80 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sarah Aebersold sold 2,695 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $25.44, for a total value of $68,560.80. Following the sale, the insider now owns 43,165 shares of the company’s stock, valued at approximately $1,098,117.60. The trade was a 5.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 21,117 shares of company stock worth $534,442. Corporate insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On BioLife Solutions

Several institutional investors and hedge funds have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC bought a new stake in shares of BioLife Solutions during the 4th quarter worth approximately $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of BioLife Solutions in the 4th quarter valued at $31,000. 1620 Investment Advisors Inc. increased its stake in shares of BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after purchasing an additional 675 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of BioLife Solutions by 27.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock worth $117,000 after buying an additional 950 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of BioLife Solutions during the 4th quarter worth $171,000. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.